We are live on ! Find out more
CHB

Global X China Biotech Innovation ETF
CHB

Delisted

CHB was delisted on the 16th of February, 2024.

Back to rankings

2 hedge funds and large institutions have $193K invested in Global X China Biotech Innovation ETF in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

15% less capital invested

Capital invested by funds: $226K → $193K (-$33.8K)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$192K – – –
Royal Bank of Canada
2
Royal Bank of Canada
Ontario, Canada
$1K – – –

CHB Hedge Fund Activity: Q2 2023 in Review

2 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Global X China Biotech Innovation ETF (CHB) for Q2 2023, worth a combined $193K — down 15% from $226K a quarter earlier.

Fund positioning in CHB was balanced in Q2 2023: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 2 institutional investors held Global X China Biotech Innovation ETF (CHB) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $193K of Global X China Biotech Innovation ETF stock for Q2 2023, down 15% quarter-over-quarter.
  • 0 funds opened new Global X China Biotech Innovation ETF positions in Q2 2023 and 0 closed out.

Based on aggregated 13F filings for Q2 2023.